Crptyde Inc (TYDE) Quote

First PR said two weeks she would be the new majority shareholder and she is not. Then the X account they run made several posts that did not happen. Ultimately it speaks to the CEO if they spew bull chit on X that never happens. Once you lie to shareholders like she has she can not be trusted perio

ASII----Smells like copper here. ;)

That's a drag. Time to sell BFIIW.

Thanks...Will hold and add...🥳

So says the confirmed serial liar. What the f does "timely manner" mean when he's 3 years past his last forecast for submitting an IDE application, a forecast he never withdrew?

Filing should happen before months end imo.

yes, her bio is the key here. she is a financial / wealth advisor - as well as an attorney. a compliance person dealing with wealth advisors more specifically. I spent years in the financial space and know these types very well. the compliance lawyers are the most risk averse, anti-business peop

Kentucky

For me, it's a little early to make a reasonable call so I agree with you on VOLUME....we have been able to get above the 200 day which I saw hitting $5.51, yeah we are above that now so that's a positive! I'll give both OldMystic and Investor a tip of the hat....I thought t

Nonsense! He's failed for over a decade!!!
Will Newbauer deliver this time,after failing for almost a year?

$FMCC WHALES 🐋

GM haters, CBDW Closed up +35.00% :)

Or further away. Each meeting is on something else FDA flagged. MK f-ed up again. Facts are facts.

yes

Shhhhh. I need to get another 100k shares.

BioMarin price target lowered to $115 from $130 at BofA
BofA analyst Jason Zemansky lowered the firm's price target on BioMarin (BMRN) to $115 from $130 and keeps a Buy rating on the shares after Ascendis Pharma (ASND) announced top-line results from ApproaCH, its pivotal trial of TransCon CN

gooooooooooooooooooooooooooood morning bobber

adios muchacho

This is not a pump.. Something going on behind the scene here. Those 5 and 10M buys are not penny flipping retail traders..
Too much size in these buys… is your key.

Need volume. Low average volume charts are meaningless. In short, if one can't liquidation a position with a market order with reasonable confidence of getting something close to last price, who cares what the chart looks like?

No mention of conversational AI
No mention of generative AI
No mention of aiWARE
No mention of Ask Veri.
No mention of AWS

Again, don't understand the Broadbean acquisition at all.

Anyway, maybe we get a continued bump in stock via rate cut

ANIP trading at between $64.32 and $65.49 premarket on very few shares, but is reflective of ANIP's current market cap + ALIM's market cap prior to merger announcement. Hopefully the start of the climb back to reasonable valuations.

What a humorous comment! 🤣

Get Ready for 100$ folks the cure to cancer
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
September 17 2024 - 7:00AM


Share On Facebook

TransCode Therapeutics, Inc. (

Raymond James upgrades New York Community into interest rate cuts
Raymond James upgraded New York Community Bancorp to Market Perform from Underperform without a price target. The firm sees "increased merit to owning liability-sensitive" banks or those with beneficial securities and deposit r

Doesn’t bashing a basher make you a basher? Bwahaaaaaa. Useless basher. Bwahaaaaaa